AstraZeneca (NYSE: AZN) reported Q4 EPS of $1.16, $0.40 worse than the analyst estimate of $1.56. Revenue for the quarter came in at $8.66 billion versus the consensus estimate of $8.59 billion.

For earnings history and earnings-related data on AstraZeneca (AZN) click here.

Earnings